Med Oncol, 2014; 31(12): 302
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
Michael Hedenus1 , Torbjorn Karlsson2 , Heinz Ludwig3 , Beate Rzychon , Marcel Felder , Bernard Roubert4 , Gunnar Birgegard2
Department of Internal Medicine, Sundsvall Hospital1, Department of Medical Sciences, Uppsala University, Uppsala, Sweden2 , 1st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria3 , Vifor Pharma, Glattbrugg, Switzerland4
Summary
This randomized trial evaluated ferric carboxymaltose without erythropoiesis-stimulating agents (ESA) for correction of anemia in cancer patients with functional iron deficiency. Patients on treatment for indolent lymphoid malignancies, who had anemia [hemoglobin (Hb) 8.5–10.5 g/dL] and functional iron deficiency [transferrin saturation (TSAT) ≤ B20 %, ferritin > 30 ng/mL (women) or > 40 ng/mL (men)], were randomized to ferric carboxymaltose (1,000 mg iron) or control. Primary end point was the mean change in Hb from baseline to weeks 4, 6 and 8 without transfusions or ESA. Difficulties with patient recruitment led to premature termination of the study. Seventeen patients (8 ferric carboxymaltose and 9 control) were included in the analysis. In the ferric carboxymaltose arm, mean Hb increase was significantly higher versus control at week 8 (p = 0.021). All ferric carboxymaltose-treated patients achieved an Hb increase >1 g/dL (control 6/9; p = 0.087), and mean TSAT was >20 % from week 2 onwards. No treatment-related adverse events were reported. In conclusion, ferric carboxymaltose without ESA effectively increased Hb and iron status in this small patient population.
(Reference link : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221625/)
